TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9559082

Group type: EXPERIMENTAL
Intervention: Dyract on etched enamel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Compoglass on unetched enamel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dyract and Compoglass on dentin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Overall comparison of Dyract and Compoglass
Number of subjects: 36
Study: 7837405

Group type: EXPERIMENTAL
Intervention: Intravenous atropine 0.5 mg administered immediately after induction of spinal anesthesia (i.v. group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intramuscular atropine 0.5 mg administered 30 min before induction of spinal anesthesia (i.m. group)
Number of subjects: 40
Study: 2904776

Group type: EXPERIMENTAL
Intervention: loratadine 10 mg once daily
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: astemizole 10 mg once daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 65
Study: 29741594

Group type: EXPERIMENTAL
Intervention: PrEP (Preexposure Prophylaxis)
Number of subjects: 4064
Study: 27009063

Group type: EXPERIMENTAL
Intervention: Chevron osteotomy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Scarf osteotomy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 73
Study: 24622724

Group type: EXPERIMENTAL
Intervention: Quantisal collection device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral-Eze collection device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gas chromatography-tandem mass spectrometry method
Number of subjects: 0
Study: 23398305

Group type: EXPERIMENTAL
Intervention: Experimental meta-intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control meta-intervention
Number of subjects: 41
Study: 20692186

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2%
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 2.0%
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: No pretreatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Storage time
Number of subjects: 72
Study: 18423151

Group type: EXPERIMENTAL
Intervention: Probiotic preparation
Number of subjects: 112
Study: 16767058

Group type: EXPERIMENTAL
Intervention: Thermoplastic neutral wrist splint for night-only wear
Number of subjects: 50
Study: 14622709

Group type: EXPERIMENTAL
Intervention: Heat and capsaicin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heat alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Capsaicin alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heat/capsaicin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rekindling
Number of subjects: 20
Study: 10828633

Group type: EXPERIMENTAL
Intervention: Petrolatum-based formulation delivered by the novel diaper
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control diaper (identical to test product without petrolatum formulation)
Number of subjects: 391
Study: 9380327

Group type: EXPERIMENTAL
Intervention: Peritoneal closure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Peritoneal nonclosure
Number of subjects: 120
Study: 8102554

Group type: EXPERIMENTAL
Intervention: Vecuronium (V) 0.01 mg kg-1 BW followed by 0.04 mg kg-1 BW
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium (A) 0.05 mg kg-1 BW followed by 0.2 mg kg-1 BW
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of V and A in the 'priming'-technique
Number of subjects: 0
Study: 2880114

Group type: EXPERIMENTAL
Intervention: Oestradiol implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oestradiol/testosterone implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo implants
Number of subjects: 0
Study: 29096997

Group type: EXPERIMENTAL
Intervention: Superior LPI (n = 285)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Nasal/temporal LPI (n = 274)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Both groups (Superior LPI and Nasal/temporal LPI)
Number of subjects: 559
Study: 26653541

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0
Study: 24433865

Group type: EXPERIMENTAL
Intervention: Elacytarabine
Number of subjects: 43
Study: 22407339

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Physical activity intervention for 5 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control Group (CG) - No intervention
Number of subjects: 150
Study: 19051099

Group type: EXPERIMENTAL
Intervention: Sodium chloride tablets (2 g) thrice daily for 4 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standardized fluid intake and diet
Number of subjects: 22
Study: 17964349

Group type: EXPERIMENTAL
Intervention: Intravenous atrial natriuretic peptide (0.025 microg/kg per min for 3 days)
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Placebo for atrial natriuretic peptide
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (0.067 mg/kg as a bolus, followed by 1.67 microg/kg per min as a 24-h continuous infusion)
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Placebo for nicorandil
Number of subjects: 1216
Study: 14694529

Group type: EXPERIMENTAL
Intervention: Increased number of epidermal Langerhans cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased expression of epidermal IL-4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mast cells, T-lymphocytes, and macrophages
Number of subjects: 0
Study: 11244200

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ancrod
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin, low‐molecular‐weight heparin, heparinoids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fraxaripine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9794982

Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis-diphtheria-tetanus immunization
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: VAERS-based studies
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Descriptive study of HHE
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Case-control study of factors affecting risk of HHE
Number of subjects: 100
Study: 8004592

Group type: EXPERIMENTAL
Intervention: Routine mass screening programs with mammography for women aged 50-69
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine mass screening programs with mammography for women aged 40-49
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual examinations with mammography and clinical breast examination (HIP and Canadian National Breast Screening Study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer intervals between examinations with mammography alone (most other trials)
Number of subjects: 0
Study: 2785684

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 75

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 75
Study: 132330

Group type: EXPERIMENTAL
Intervention: Loading dose therapy with phenytoin (4 doses of 4.4 to 6.3 mg/kg/dose given 8-hourly and then 6 mg/kg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional dose therapy with phenytoin (5 to 9 mg/kg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Loading dose therapy with phenytoin
Number of subjects: 13
Study: 31171011

Group type: EXPERIMENTAL
Intervention: Structured Process Informed by Data, Evidence and Research (SPIDER)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7
Study: 29261676

Group type: EXPERIMENTAL
Intervention: Authoritarian mothers
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Authoritarian partners
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Permissive mothers
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Active families (rated by partners)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Children who watched television
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Overall television viewing
Number of subjects: 487
Study: 26262828

Group type: EXPERIMENTAL
Intervention: Xtampza ER (extended-release oxycodone)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 740
Study: 23836093

Group type: EXPERIMENTAL
Intervention: Peer-support intervention
Number of subjects: 33
Study: 21616657

Group type: EXPERIMENTAL
Intervention: Intrathecal isobaric bupivacaine
Number of subjects: 70
Study: 19711465

Group type: EXPERIMENTAL
Intervention: Postoperative vinorelbine and cisplatin (BR.10)
Number of subjects: 1987

Group type: EXPERIMENTAL
Intervention: Chemotherapy (BR.18)
Number of subjects: 1987

Group type: EXPERIMENTAL
Intervention: Erlotinib (BR.21)
Number of subjects: 1987

Group type: COMPARATOR
Intervention: Placebo (BR.21)
Number of subjects: 1987
Study: 22828707

Group type: EXPERIMENTAL
Intervention: Operator assessment of TIMI flow
Number of subjects: 3345

Group type: EXPERIMENTAL
Intervention: Operator assessment of MBG
Number of subjects: 3345

Group type: EXPERIMENTAL
Intervention: Operator assessment of final TIMI flow
Number of subjects: 3345

Group type: EXPERIMENTAL
Intervention: Operator assessment of final MBG
Number of subjects: 3345

Group type: EXPERIMENTAL
Intervention: Post-PCI TIMI 3 flow and MBG 2 to 3
Number of subjects: 3345

Group type: COMPARATOR
Intervention: Discordant groups of Op and ACL assessments
Number of subjects: 3345
Study: 15994258

Group type: EXPERIMENTAL
Intervention: Creatine (creatine monohydrate 5.7 g, glucose 35 g)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (glucose polymer 40.7 g)
Number of subjects: 38
Study: 12586855

Group type: COMPARATOR
Intervention: Placebo (P) injections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training and Placebo (RT+P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly injections of testosterone (T; 100 mg/wk)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training and Testosterone (RT+T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individuals not on Testosterone
Number of subjects: 0
Study: 10227334

Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg BID)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 7777307

Group type: EXPERIMENTAL
Intervention: Bandage contact lens with topical nonsteroidal anti-inflammatory drug (0.5% ketorolac tromethamine)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Bandage contact lens
Number of subjects: 47

Group type: COMPARATOR
Intervention: Pressure patching
Number of subjects: 47
Study: 2108883

Group type: EXPERIMENTAL
Intervention: 3.75 mg leuprorelin acetate depot
Number of subjects: 43
Study: 7006069

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (50 mg bid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg tid)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (single-blind period)
Number of subjects: 24
Study: 30481942

Group type: EXPERIMENTAL
Intervention: Risk rating model based on non-genetic factors using decision trees
Number of subjects: 783

Group type: COMPARATOR
Intervention: Control group (non-cancer cases)
Number of subjects: 783
Study: 27782922

Group type: EXPERIMENTAL
Intervention: 8-week seated yoga program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group setting for yoga
Number of subjects: 0
Study: 23657754

Group type: EXPERIMENTAL
Intervention: Peer Specialists (PSs) added to intensive case management teams for 1 year
Number of subjects: 282

Group type: COMPARATOR
Intervention: Usual Care (no Peer Specialists)
Number of subjects: 282
Study: 23963145

Group type: EXPERIMENTAL
Intervention: Chemoradiation (4 courses of intravenous carboplatin on day 1 and oral vinorelbin on days 1 and 8 with 3-week intervals, plus radiotherapy 42 Gy/15 starting at the second chemotherapy course)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Chemotherapy alone (4 courses of intravenous carboplatin on day 1 and oral vinorelbin on days 1 and 8 with 3-week intervals)
Number of subjects: 191
Study: 21936885

Group type: COMPARATOR
Intervention: SP (sulphadoxine‐pyrimethamine)
Number of subjects: 109

Group type: COMPARATOR
Intervention: SP+AQ (sulphadoxine‐pyrimethamine + amodiaquine)
Number of subjects: 109

Group type: COMPARATOR
Intervention: SP+AS (sulphadoxine‐pyrimethamine + artesunate)
Number of subjects: 109

Group type: COMPARATOR
Intervention: SP
Number of subjects: 109

Group type: COMPARATOR
Intervention: SP+AQ
Number of subjects: 109

Group type: COMPARATOR
Intervention: SP+AS
Number of subjects: 109
Study: 18245761

Group type: EXPERIMENTAL
Intervention: Individually tailored geriatric treatment
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 174
Study: 16785188

Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg b.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy volunteers (placebo)
Number of subjects: 12
Study: 12865879

Group type: EXPERIMENTAL
Intervention: Vasogen's immune modulation therapy (IMT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 18
Study: 11053475

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ang II infusion (5 ng Ang II/kg per min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Irbesartan premedication plus Ang II infusion (5 ng Ang II/kg per min)
Number of subjects: 9
Study: 8865704

Group type: EXPERIMENTAL
Intervention: 25g glucose infusion in 30 minutes (group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50g glucose infusion in 30 minutes (group 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (25g and 50g glucose infusion)
Number of subjects: 20
Study: 1353028

Group type: EXPERIMENTAL
Intervention: CV 205‐502
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 24
Study: 6338091

Group type: EXPERIMENTAL
Intervention: Ultraviolet (UV) light treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study: 30074217

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with low-frequency repetitive transcranial magnetic stimulation (rTMS), 3 days per week for 4 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Acupuncture cooperated with sham rTMS treatment, 3 days per week for 4 weeks
Number of subjects: 78
Study: 26840902

Group type: EXPERIMENTAL
Intervention: Ketorolac NS 31.5 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sumatriptan NS 20 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 24411080

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Surgical resection (RES)
Number of subjects: 119
Study: 21969420

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus standard treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 60
Study: 20033176

Group type: EXPERIMENTAL
Intervention: iomeprol 300 mgI/ml
Number of subjects: 8931

Group type: EXPERIMENTAL
Intervention: iopromide 300 mgI/ml
Number of subjects: 8931

Group type: EXPERIMENTAL
Intervention: iopamidol 300 mgI/ml
Number of subjects: 8931

Group type: EXPERIMENTAL
Intervention: iohexol 300 mgI/ml
Number of subjects: 8931

Group type: EXPERIMENTAL
Intervention: ioversol 320 mgI/ml
Number of subjects: 8931

Group type: COMPARATOR
Intervention: Control group (patients aged 60 years or over)
Number of subjects: 8931

Group type: COMPARATOR
Intervention: Control group (patients with past history of adverse reactions)
Number of subjects: 8931

Group type: COMPARATOR
Intervention: Control group (patients receiving contrast media previously)
Number of subjects: 8931

Group type: COMPARATOR
Intervention: Control group (patients aged 59 years or less)
Number of subjects: 8931

Group type: COMPARATOR
Intervention: Control group (first period of administration)
Number of subjects: 8931

Group type: COMPARATOR
Intervention: Control group (late period of administration)
Number of subjects: 8931

Group type: COMPARATOR
Intervention: Control group (patients receiving contrast media for the first time)
Number of subjects: 8931
Study: 18709675

Group type: EXPERIMENTAL
Intervention: Levodopa administration after overnight withdrawal of dopaminergic medications.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cold water immersion test for PD patients 'off'-medication.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Comparison of pain sensitivity change scores between fluctuators and stable responders/dyskinetic groups.
Number of subjects: 50
Study: 15952055

Group type: EXPERIMENTAL
Intervention: Epirubicin-based chemotherapy
Number of subjects: 579
Study: 12575964

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2064
Study: 12037652

Group type: EXPERIMENTAL
Intervention: Monounsaturated fat (MUFA) from extra virgin olive oil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saturated fat (SFA) from cream
Number of subjects: 14
Study: 10194172

Group type: EXPERIMENTAL
Intervention: APRV with spontaneous breathing
Number of subjects: 24

Group type: COMPARATOR
Intervention: APRV without spontaneous breathing
Number of subjects: 24

Group type: COMPARATOR
Intervention: PSV
Number of subjects: 24
Study: 7785016

Group type: EXPERIMENTAL
Intervention: Nasal cannulae
Number of subjects: 99

Group type: COMPARATOR
Intervention: Venturi face masks
Number of subjects: 99
Study: 2211266

Group type: EXPERIMENTAL
Intervention: Chemotherapy (3 cycles of 120 hr 5-FU infusion 1 g/m2/day plus Cis platin 100 mg/m2 on day 1 of each cycle)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Definitive local treatment (surgery and post-operative radiation or radiation alone)
Number of subjects: 75
Study: 7407477

Group type: EXPERIMENTAL
Intervention: Cooked lentils (50 g carbohydrate portion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cooked soya beans (50 g carbohydrate portion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wholemeal bread (control)
Number of subjects: 0
Study: 31742460

Group type: EXPERIMENTAL
Intervention: Mobile multimedia message service (MMS) messages communicating the risks of hookah tobacco use
Number of subjects: 156
Study: 27642658

Group type: EXPERIMENTAL
Intervention: Positive affect in personal events (Study 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Positive affect in interpersonal events (Study 2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Positive affect in fictional characters (Studies 3 and 4)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Personification of emotions (Study 5)
Number of subjects: 24
Study: 25837980

Group type: EXPERIMENTAL
Intervention: SEC-coated group (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PMEA-coated group (n = 20)
Number of subjects: 40
Study: 23735726

Group type: EXPERIMENTAL
Intervention: Computer-assisted self-management (CASM)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: CASM plus DD-specific problem solving (CAPS)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Computer-administered minimal supportive intervention
Number of subjects: 392
Study: 21439397

Group type: EXPERIMENTAL
Intervention: Betamethasone (12 mg/kg, two doses intramuscularly)
Number of subjects: 68
Study: 20374316

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg four times per day for 12 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (same dosage and schedule as erythromycin)
Number of subjects: 108
Study: 17600085

Group type: EXPERIMENTAL
Intervention: Dexamethasone (40 mg over 30 min, 16 h and 1 h before chemotherapy)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No dexamethasone administration (control)
Number of subjects: 8
Study: 15140663

Group type: EXPERIMENTAL
Intervention: Two doses of sodium phosphate solution
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Sodium phosphate solution (both single and two doses)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Polyethylene glycol solution
Number of subjects: 299
Study: 11920277

Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 400

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 400
Study: 10169390

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b
Number of subjects: 583

Group type: COMPARATOR
Intervention: Melphalan and prednisone
Number of subjects: 583
Study: 7930984

Group type: EXPERIMENTAL
Intervention: Sickle cell trait
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 28
Study: 3385217

Group type: EXPERIMENTAL
Intervention: C18:0 PAF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C16:0 and C18:0 PAFs (1:9 ratio)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C16:0 and C18:0 PAFs (dose-dependent intradermal injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of C16:0 and C18:0 PAFs (3:1 or 1:9 ratio)
Number of subjects: 0
Study: 31066013

Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg/day
Number of subjects: 172

Group type: COMPARATOR
Intervention: Fluconazole 100-200 mg/day (intravenous or oral)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Micafungin and Fluconazole
Number of subjects: 172
Study: 29898701

Group type: EXPERIMENTAL
Intervention: CVD risk information and web‐based lifestyle advice
Number of subjects: 716
Study: 27623967

Group type: EXPERIMENTAL
Intervention: Very low-calorie-ketogenic diet (n=22)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low-calorie diet (n=23)
Number of subjects: 45
Study: 23828452

Group type: EXPERIMENTAL
Intervention: 200-1000 ml oral rehydration solution
Number of subjects: 60
Study: 22177742

Group type: EXPERIMENTAL
Intervention: Internet delivered CBT (iCBT) program (Brighten Your Mood Program)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 55
Study: 20335146

Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment for 12 months (n=40)
Number of subjects: 79

Group type: COMPARATOR
Intervention: No rosuvastatin treatment (n=39)
Number of subjects: 79
Study: 18710018

Group type: EXPERIMENTAL
Intervention: Standard tracheal tubes (Group P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wire-reinforced tracheal tubes (Group S)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Group P and Group S)
Number of subjects: 40